{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:21:58Z","timestamp":1793910118308,"version":"4.8.0"},"reference-count":47,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"crossref","award":["2024ZKY049"],"award-info":[{"award-number":["2024ZKY049"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the associations between inhaled corticosteroids (ICSs) and adverse events (AEs) in adults with asthma or chronic obstructive pulmonary disease (COPD) and to explore variations by ICS type and dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>Medline\/PubMed, Embase, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were searched from inception to 20 February 2025. Data extraction and synthesis were performed, estimating risk ratios (RRs) with 95% confidence intervals (CI) or credible intervals (CrI) through pairwise and network meta-analysis (NMA), and an NMA using the Emax model was employed to find the dose\u2013response relationships of the AEs of each ICS. Risk of bias was evaluated across both pairwise and NMAs. The certainty of evidence, based on the GRADE approach, was assessed exclusively for the NMA estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults diagnosed with asthma or COPD treated with ICSs compared with non-ICS controls or those receiving different types or doses of ICSs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary outcomes were AEs, including pneumonia, oral candidiasis, upper respiratory tract infection (URTI), fracture, diabetes, cataract and plasma cortisol abnormalities. Secondary outcomes included efficacy-related endpoints: asthma exacerbations, COPD exacerbations and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>129 trials (120\u2009900 participants) were included. According to pairwise meta-analysis, ICSs were associated with a higher risk of pneumonia (RR 1.49, 95% CI 1.38 to 1.61) and oral candidiasis (RR 2.29, 95% CI 2.01 to 2.60) and with a slightly higher risk of URTI (RR 1.17, 95% CI 1.10 to 1.25), compared with control. Besides, ICSs were linked to a reduced risk of asthma exacerbations (RR 0.30, 95% CI 0.20 to 0.45) and COPD exacerbations (RR 0.90, 95% CI 0.86 to 0.94) vs control. The results of the NMA that explored differences by ICS type showed that beclomethasone and fluticasone increased pneumonia risk compared with control, with absolute risk increases of up to 2.3%. Fluticasone also showed a slightly higher pneumonia risk than budesonide. Besides, mometasone, beclomethasone, budesonide and fluticasone were associated with increased risk of oral candidiasis, with the highest increase observed for mometasone (4.3%). In contrast, ciclesonide consistently showed lower risk across comparisons, reducing oral candidiasis by up to 4.5% with other ICSs. Fluticasone modestly increased URTI, while ciclesonide reduced it. Budesonide and mometasone were also associated with a small increase in cataract risk. Most of the outcomes reported here were supported by moderate- to high-certainty evidence. Furthermore, the dose\u2013response relationship estimated from the Emax model indicated significant associations between fluticasone dose and the risks of pneumonia and URTI, between multiple ICS doses and oral candidiasis and between budesonide dose and cataract.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICSs are correlated with the escalated risk of pneumonia, oral candidiasis and URTI in adult patients with asthma or COPD, but ICSs could reduce asthma exacerbations and COPD exacerbations. Fluticasone, beclomethasone, budesonide and mometasone are independently linked to certain AEs, and some Emax dose\u2013response relationships are detected.<\/jats:p>\n                    <jats:p>Our findings may help guide individualised ICS use by informing benefit-risk considerations across various formulations and dosing regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024527797.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjebm-2024-113216","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T18:20:13Z","timestamp":1763230813000},"page":"23-35","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose\u2013response meta-analyses"],"prefix":"10.1136","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0450-1169","authenticated-orcid":false,"given":"Xiaofeng","family":"Pu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9094-2986","authenticated-orcid":false,"given":"Yinhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4733-7536","authenticated-orcid":false,"given":"Li","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6427-8514","authenticated-orcid":false,"given":"Yunbei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0049-3548","authenticated-orcid":false,"given":"Xinrui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Nanchong Key Laboratory of lndividualized Drug Therapy, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong 637000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-3503","authenticated-orcid":false,"given":"Maolin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3639-3256","authenticated-orcid":false,"given":"Zhengji","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0140-8657","authenticated-orcid":false,"given":"Mengyao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-3205","authenticated-orcid":false,"given":"Guojun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"2026012102050892000_31.1.23.1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","author":"Soriano","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012102050892000_31.1.23.2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . GLOBAL strategy for prevention, diagnosis and management of COPD: 2024 report. Available: https:\/\/goldcopd.org\/2024-gold-report [accessed 02 Apr 2024]"},{"key":"2026012102050892000_31.1.23.3","unstructured":"Global Initiative for Asthma . POCKET guide for asthma management and prevention. 2023. Available: https:\/\/ginasthma.org\/reports [Accessed 02 Apr 2024]."},{"key":"2026012102050892000_31.1.23.4","doi-asserted-by":"crossref","first-page":"105950","DOI":"10.1016\/j.intimp.2019.105950","article-title":"Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials","volume":"77","author":"Yang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2026012102050892000_31.1.23.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2011.160028"},{"key":"2026012102050892000_31.1.23.6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s15010-018-1229-y","article-title":"Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis","volume":"47","author":"Yang","year":"2019","journal-title":"Infection"},{"key":"2026012102050892000_31.1.23.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-019-0150-x","article-title":"Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study","volume":"29","author":"Price","year":"2019","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026012102050892000_31.1.23.8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","article-title":"Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respir Med"},{"key":"2026012102050892000_31.1.23.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108960"},{"key":"2026012102050892000_31.1.23.10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events","volume":"211","author":"Bloom","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012102050892000_31.1.23.11","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/8209978","article-title":"Inhaled Corticosteroid Exposure and Risk of Cataract in Patients with Asthma and COPD: A Systematic Review and Meta-Analysis","volume":"2023","author":"Savran","year":"2023","journal-title":"J Ophthalmol"},{"key":"2026012102050892000_31.1.23.12","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.2147\/COPD.S54927","article-title":"Airflow obstruction: is it asthma or is it COPD?","volume":"11","author":"Rogliani","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012102050892000_31.1.23.13","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.37765\/ajmc.2021.88587","article-title":"Determinants of ICS therapy adherence in patients with asthma","volume":"27","author":"Wang","year":"2021","journal-title":"Am J Manag Care"},{"key":"2026012102050892000_31.1.23.14","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.03200"},{"key":"2026012102050892000_31.1.23.15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2147\/COPD.S234349","article-title":"Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study","volume":"15","author":"Chen","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012102050892000_31.1.23.16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/imj.13611","article-title":"Inappropriate inhaled corticosteroid prescribing in chronic obstructive pulmonary disease patients","volume":"47","author":"Harrison","year":"2017","journal-title":"Intern Med J"},{"key":"2026012102050892000_31.1.23.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-023-00347-6","article-title":"Rational use of inhaled corticosteroids for the treatment of COPD","volume":"33","author":"Quint","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026012102050892000_31.1.23.18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14040"},{"key":"2026012102050892000_31.1.23.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.07.011"},{"key":"2026012102050892000_31.1.23.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01789-7","article-title":"Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta-analysis","volume":"22","author":"Pu","year":"2021","journal-title":"Respir Res"},{"key":"2026012102050892000_31.1.23.21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12325-024-02823-y","article-title":"Pharmacological Basis of Differences in Dose Response, Dose Equivalence, and Duration of Action of Inhaled Corticosteroids","volume":"41","author":"Daley-Yates","year":"2024","journal-title":"Adv Ther"},{"key":"2026012102050892000_31.1.23.22","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S175047"},{"key":"2026012102050892000_31.1.23.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026012102050892000_31.1.23.24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012102050892000_31.1.23.25","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620965145","article-title":"Effect of once-daily fluticasone furoate\/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial","volume":"14","author":"Maltais","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"2026012102050892000_31.1.23.26","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012102050892000_31.1.23.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"2026012102050892000_31.1.23.28","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"key":"2026012102050892000_31.1.23.29","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"2026012102050892000_31.1.23.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"2026012102050892000_31.1.23.31","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X20983315"},{"key":"2026012102050892000_31.1.23.32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/psp4.12091","article-title":"Model-Based Network Meta-Analysis: A Framework for Evidence Synthesis of Clinical Trial Data","volume":"5","author":"Mawdsley","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026012102050892000_31.1.23.33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/sim.9270","article-title":"Methods to assess evidence consistency in dose-response model based network meta-analysis","volume":"41","author":"Pedder","year":"2022","journal-title":"Stat Med"},{"key":"2026012102050892000_31.1.23.34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1517\/14740338.2015.1057494","article-title":"Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia","volume":"14","author":"Liapikou","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"2026012102050892000_31.1.23.35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/15412555.2020.1787369","article-title":"Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis","volume":"17","author":"Zhang","year":"2020","journal-title":"COPD"},{"key":"2026012102050892000_31.1.23.36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5644\/ama2006-124.141","article-title":"Inhaled corticosteroids and incident pneumonia in patients with asthma: Systematic review and meta-analysis","volume":"44","author":"Bansal","year":"2015","journal-title":"Acta Med Acad"},{"key":"2026012102050892000_31.1.23.37","article-title":"Inhaled Corticosteroids as an Associated Risk Factor for Asthmatic Pneumonia: A Literature Review","volume":"12","author":"Htun","year":"2020","journal-title":"Cureus"},{"key":"2026012102050892000_31.1.23.38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4168\/aair.2019.11.6.795","article-title":"Inhaled Corticosteroids in Asthma and the Risk of Pneumonia","volume":"11","author":"Kim","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026012102050892000_31.1.23.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-1025-1","article-title":"Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia","volume":"19","author":"Ekbom","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026012102050892000_31.1.23.40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5152\/TurkThoracJ.2019.17011916","article-title":"The Frequency and Risk Factors for Oropharyngeal Candidiasis in Adult Asthma Patients Using Inhaled Corticosteroids","volume":"20","author":"Erdo\u011fan","year":"2019","journal-title":"Turk Thorac J"},{"key":"2026012102050892000_31.1.23.41","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0075-2021","article-title":"Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD","volume":"30","author":"Miravitlles","year":"2021","journal-title":"Eur Respir Rev"},{"key":"2026012102050892000_31.1.23.42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12890-020-01315-3","article-title":"Association between inhaled corticosteroids and upper respiratory tract infection in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2026012102050892000_31.1.23.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01589.x"},{"key":"2026012102050892000_31.1.23.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(03)01859-1"},{"key":"2026012102050892000_31.1.23.45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2018.04.006","article-title":"Assessment of hair cortisol as a potential biomarker for possible adrenal suppression due to inhaled corticosteroid use in children with asthma: A retrospective observational study","volume":"56","author":"Smy","year":"2018","journal-title":"Clin Biochem"},{"key":"2026012102050892000_31.1.23.46","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.10933"},{"key":"2026012102050892000_31.1.23.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-023-02602-5","article-title":"Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"23","author":"Peng","year":"2023","journal-title":"BMC Pulm Med"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2024-113216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:05:46Z","timestamp":1768989946000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2024-113216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,21]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjebm-2024-113216"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2024-113216","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}